Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Glucose Metabolism in Youths with Cystic Fibrosis: Insights from Continuous Glucose Monitoring
Highlight
• Continuous glucose monitoring (CGM) detects subtle glucose abnormalities in children with cystic fibrosis (CF) before overt diabetes develops.
• The CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) improves glucose control metrics measured by CGM in pediatric patients.
• Early glucose abnormalities (time above 140 mg/dL >10%) correlate with less clinical improvement in lung function and weight after ETI initiation.
• CGM offers a sensitive tool to monitor metabolic changes and may inform prognosis and management in youth with CF undergoing ETI therapy.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.